|
Adjuvant Radiation Therapy in Treating Patients With Resected Desmoplastic Melanoma Clinical Trials Facts presented on Clinical Trials Search is not designed to be a substitute for certified medical advice, travels to or treatment with a real dr.. We aren't doctors. Always consult your mD on Adjuvant Radiation Therapy in Treating Patients With Resected Desmoplastic Melanoma conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Adjuvant Radiation Therapy in Treating Patients With Resected Desmoplastic Melanoma Clinical research trials and Adjuvant Radiation Therapy in Treating Patients With Resected Desmoplastic Melanoma medical trials occur in many of places across the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the effectiveness of new does drugs. The role of the studies / undertakings is to figure out certain human healthcare questions. Clinical trials are a popular means for doctors, government agencies, and private sector corporations to locate treatments for all forms of circumstances, including Adjuvant Radiation Therapy in Treating Patients With Resected Desmoplastic Melanoma. Adjuvant Radiation Therapy in Treating Patients With Resected Desmoplastic Melanoma Clinical Trials and other clinical trials permit volunteers to get medical treatment options before they are available to the masses. Most times the human subjects acquire treatment for free of charge, and sometimes they are paid for their time. Occasionally there is a cost for a Adjuvant Radiation Therapy in Treating Patients With Resected Desmoplastic Melanoma clinical trial. Participants oftentimes recieve the finest healthcare available for their Adjuvant Radiation Therapy in Treating Patients With Resected Desmoplastic Melanoma condition. Dangers are a reality, nonetheless, and might include extra or frequent physician calls, health hazards (potentially life-endangering), and/or the treatment being ineffectual. Trials are federally regulated with strict guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > Adjuvant Radiation Therapy in Treating Patients With Resected Desmoplastic Melanoma  Adjuvant Radiation Therapy in Treating Patients With Resected Desmoplastic Melanoma
Adjuvant Radiation Therapy in Treating Patients With Resected Desmoplastic Melanoma
For Condition: stage 3 melanoma,stage 1 melanoma,Recurrent Melanoma,stage 2 melanoma
Status: Recruiting
Sponsor(s): North Central Cancer Treatment Group , National Cancer Institute (NCI)
Synopsis: RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Giving radiation therapy after surgery may kill any tumor cells remaining after surgery. PURPOSE: Phase II trial to study the effectiveness of adjuvant radiation therapy in treating patients who have resecteddesmoplastic melanoma.
Details: OBJECTIVES: - Determine the recurrence rates of patients with desmoplastic melanoma treated with adjuvant radiotherapy after surgical resection. - Determine the disease-free and overall survival of patients treated with this regimen. - Determine the immediate and long-term morbidity of patients treated with this regimen. OUTLINE: This is a multicenter study. Within 8 weeks after surgical resection, patients undergo radiotherapy twice weekly over 2.5 weeks in the absence of unacceptable toxicity. Patients are followed every 3 months for 2 years and then every 6 months for 3 years. PROJECTED ACCRUAL: A total of 40 patients will be accrued for this study.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: DISEASE CHARACTERISTICS: - Histologically confirmed desmoplastic melanoma - Locally recurrent OR at least 1 mm in depth - Recurrent tumor is defined as a tumor found no more than 2 cm from the previous excision or within the surgical bed (which includes the extent of previous skin flaps) - Disease resected using standard wide resection or Moh's surgery - Histologically negative margins - Tumors on proximal extremities must have a 2 cm negative margin - Tumors on the head or neck or distal extremities may have margins less than 2 cm provided they are negative - No melanoma with focally desmoplastic features, in which the desmoplastic melanoma is not the predominant histologic pattern of the tumor - No nondesmoplastic neurotropic or nondesmoplastic spindle cell melanoma - No evidence of metastatic disease (local nodal disease allowed) PATIENT CHARACTERISTICS: Age - 18 and over Performance status - ECOG 0-2 Life expectancy - At least 1 year Hematopoietic - Not specified Hepatic - Not specified Renal - Not specified Other - Not pregnant - Negative pregnancy test - Fertile patients must use effective contraception - No other malignancy within the past 5 years except basal cell or squamous cell skin cancer or carcinoma in situ of the cervix - No nonhealing surgical wound - No active infection at the surgical site PRIOR CONCURRENT THERAPY: Biologic therapy - No concurrent adjuvant immunotherapy Chemotherapy - No concurrent adjuvant chemotherapy Endocrine therapy - Not specified Radiotherapy - No prior radiotherapy to the focused site of this study Surgery - See Disease Characteristics
Total Enrollment:
Location and Contact Information:
Overall Study Official:
BarbaraPockaj, Study Chair, Mayo Clinic Scottsdale
CCOP - Wichita *Recruiting*
Wichita, Kansas, 67214-3882
United States
Recruiting Shaker Dakhil 316-268-5784
Mayo Clinic Cancer Center *Recruiting*
Rochester, Minnesota, 55905
United States
Recruiting Steven Alberts 507-284-2511
CCOP - Sioux Community Cancer Consortium *Recruiting*
Sioux Falls, South Dakota, 57104
United States
Recruiting Loren Tschetter 605-328-8044
CCOP - Cedar Rapids Oncology Project *Recruiting*
Cedar Rapids, Iowa, 52403-1206
United States
Recruiting Martin Wiesenfeld 319-363-8303
Rapid City Regional Hospital *Recruiting*
Rapid City, South Dakota, 57709
United States
Recruiting Larry Ebbert 605-341-8704
CCOP - Dayton *Recruiting*
Dayton, Ohio, 45429
United States
Recruiting Howard Gross 937-395-8678
Medcenter One Health System *Recruiting*
Bismark, North Dakota, 58501-5505
United States
Recruiting Edward Wos 701-323-5741
CCOP - Mayo Clinic Scottsdale Oncology Program *Recruiting*
Scottsdale, Arizona, 85259-5404
United States
Recruiting Barbara Pockaj 480-301-8000
Mayo Clinic *Recruiting*
Jacksonville, Florida, 32224
United States
Recruiting Edith Perez 904-953-0118
CCOP - Iowa Oncology Research Association *Recruiting*
Des Moines, Iowa, 50309-1016
United States
Recruiting Roscoe Morton 515-244-7586
Siouxland Hematology-Oncology *Recruiting*
Sioux City, Iowa, 51101-1733
United States
Recruiting Donald Wender 712-252-0088
CCOP - Carle Cancer Center *Recruiting*
Urbana, Illinois, 61801
United States
Recruiting Kendrith Rowland 217-383-4083
Additional Information:
Study ID Numbers: CDR0000301633; NCCTG-N0275
Study Start Date:
Record last reviewed: July 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00060333
Other Recurrent Melanoma Studies:
1. Vaccine Therapy Followed by Biological Therapy in Treating Patients With Stage III or Stage IV Melanoma
2. SU5416 in Treating Patients With Metastatic Melanoma That Has Been Previously Treated
3. Chemotherapy Plus Bone Marrow Transplantation in Treating Patients With Metastatic Melanoma
4. Tipifarnib in Treating Patients With Metastatic Malignant Melanoma
5. Denileukin Diftitox in Treating Patients With Metastatic Melanoma or Metastatic Kidney Cancer
Related Studies:
Other Recurrent Melanoma Clinical Trials
Other Iowa Clinical Trials
Other Sioux City Clinical Trials
Adjuvant Radiation Therapy in Treating Patients With Resected Desmoplastic Melanoma
|
|
|
|
|
|
|
|
